AVITA Medical Reports Modest Revenue Growth Amid Cost Cuts and Leadership Changes
Event summary
- AVITA Medical reported $19.3M in Q1 2026 revenue, up 4% YoY and 10% sequentially, driven by Cohealyx and RECELL utilization.
- Cary Vance appointed as President and CEO, with Jan Stern Reed becoming independent Chair of the Board.
- Gross profit margin at 81.7%, down from 84.7% YoY due to product mix shifts and inventory adjustments.
- Operating expenses decreased 11% YoY to $24.5M, reflecting cost optimization initiatives.
- Secured a 10-year BARDA agreement valued at up to $25.5M for U.S. burn emergency preparedness.
The big picture
AVITA Medical's Q1 2026 results reflect stabilization efforts and strategic shifts in leadership and product portfolio. The company's focus on cost optimization and recurring revenue streams, such as the BARDA agreement, aligns with broader trends in the acute wound care sector toward sustainable growth and operational efficiency. The leadership changes signal confidence in the company's strategic direction, but execution remains critical amid competitive and reimbursement dynamics.
What we're watching
- Revenue Trajectory
- Whether AVITA can sustain sequential revenue growth amid reimbursement normalization and product mix shifts.
- Cost Discipline
- The pace at which operating expense reductions will impact profitability and cash flow.
- Regulatory Momentum
- How the BARDA agreement and international regulatory clearances will drive adoption and revenue.
Related topics